Breaking genetic shackles: The advance of base editing in genetic disorder treatment

Front Pharmacol. 2024 Mar 6:15:1364135. doi: 10.3389/fphar.2024.1364135. eCollection 2024.

Abstract

The rapid evolution of gene editing technology has markedly improved the outlook for treating genetic diseases. Base editing, recognized as an exceptionally precise genetic modification tool, is emerging as a focus in the realm of genetic disease therapy. We provide a comprehensive overview of the fundamental principles and delivery methods of cytosine base editors (CBE), adenine base editors (ABE), and RNA base editors, with a particular focus on their applications and recent research advances in the treatment of genetic diseases. We have also explored the potential challenges faced by base editing technology in treatment, including aspects such as targeting specificity, safety, and efficacy, and have enumerated a series of possible solutions to propel the clinical translation of base editing technology. In conclusion, this article not only underscores the present state of base editing technology but also envisions its tremendous potential in the future, providing a novel perspective on the treatment of genetic diseases. It underscores the vast potential of base editing technology in the realm of genetic medicine, providing support for the progression of gene medicine and the development of innovative approaches to genetic disease therapy.

Keywords: adenine base editors; base editing; cytosine base editors; delivery strategies; genetic diseases.

Publication types

  • Review

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China (No. 31970930), Hubei Natural Science Foundation (Nos. 2020CFA069 and 2018CFB434), and Neuroscience Team Development. Project of Wuhan University of Science and Technology (No. 1180002).